financetom
Business
financetom
/
Business
/
-- Converge Technology Solutions Brief: Keeps Outperform Rating But Target Lifted To C$7 From $6 at National Bank On "Another Quarter of Strong Cash Flows"
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
-- Converge Technology Solutions Brief: Keeps Outperform Rating But Target Lifted To C$7 From $6 at National Bank On "Another Quarter of Strong Cash Flows"
May 9, 2024 12:53 PM

03:35 PM EDT, 05/09/2024 (MT Newswires) --

Price: 5.09, Change: -0.64, Percent Change: -11.17

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ecolab raises full-year profit forecast after strong Q3 earnings
Ecolab raises full-year profit forecast after strong Q3 earnings
Nov 3, 2024
Oct 29 (Reuters) - Water solutions company Ecolab ( ECL ) on Tuesday raised its full-year adjusted earnings forecast after reporting a third-quarter profit beat, bolstered by robust demand for its products and lower costs. Ecolab ( ECL ) serves industries ranging from manufacturing and food and beverage processing to healthcare and petrochemicals. Manufacturing activity in the United States, Ecolab's...
Nova Leap Health Expands Into Nova Scotia With $1.4 Million Acquisition of Two Home Care Services Companies
Nova Leap Health Expands Into Nova Scotia With $1.4 Million Acquisition of Two Home Care Services Companies
Nov 3, 2024
09:17 AM EDT, 10/29/2024 (MT Newswires) -- Nova Leap Health ( NVLPF ) , a home health care organization, on Tuesday said it will acquire two affiliated home care services companies in Nova Scotia for $1.4 million. According to Nova Leap, the targets reported combined revenue of $2.6 million and net income of $235,000 for the 2023 fiscal year. The...
Incyte raises 2024 sales forecast for top-selling drug Jakafi
Incyte raises 2024 sales forecast for top-selling drug Jakafi
Nov 3, 2024
Oct 29 (Reuters) - Incyte ( INCY ) beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong. Jakafi is approved for use in patients with two types of blood cancers called myelofibrosis and polycythemia vera (PV). The treatment is also approved for acute graft-versus-host disease...
Stanley Black & Decker Q3 Earnings: Revenue Misses, Cost Savings Drive Margin Gains, Narrows 2024 EPS Guidance & More
Stanley Black & Decker Q3 Earnings: Revenue Misses, Cost Savings Drive Margin Gains, Narrows 2024 EPS Guidance & More
Nov 3, 2024
Stanley Black & Decker Inc ( SWK ) shares are trading lower after the company reported mixed third-quarter results and narrowed its 2024 guidance. SWK reported a third-quarter sales decline of 5.2% year over year to $3.751 billion, missing the consensus estimate of $3.804 billion. Revenue declined as DEWALT growth was offset by mixed-end market demand; infrastructure divestiture impacted revenue...
Copyright 2023-2026 - www.financetom.com All Rights Reserved